Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase 1
Completed
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- QLT Inc.
- Registration Number
- NCT00007969
- Locations
- ๐บ๐ธ
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
๐บ๐ธMount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
๐บ๐ธUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
Phase 1
Completed
- Conditions
- Benign Prostatic Hyperplasia
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- QLT Inc.
- Registration Number
- NCT00077012
- Locations
- ๐บ๐ธ
George Washington University Medical Center, Washington, District of Columbia, United States
๐บ๐ธCarolina Urologic Research Center, Myrtle Beach, South Carolina, United States
๐บ๐ธRaymond Fay, MD, Inc, San Francisco, California, United States
Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin.
Phase 3
Terminated
- Conditions
- Gorlin SyndromeNevoid Basal Cell Carcinoma SyndromeBasal Cell Carcinoma
- First Posted Date
- 2002-11-19
- Last Posted Date
- 2011-03-16
- Lead Sponsor
- QLT Inc.
- Registration Number
- NCT00049959
Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2002-11-06
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00048633
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธFlorida Oncology Associates, Jacksonville, Florida, United States
๐บ๐ธArlington Cancer Center, Arlington, Texas, United States
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Terminated
- Conditions
- Stage IIIb Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT00042302
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Terminated
- Conditions
- Stage IV Non-small Cell Lung CancerStage IIIb Non-small Cell Lung Cancer
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- QLT Inc.
- Target Recruit Count
- 490
- Registration Number
- NCT00042315
ยฉ Copyright 2025. All Rights Reserved by MedPath